Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

References

• PaulSKantarjianHJabbourEJAdult Acute Lymphoblastic LeukemiaMayo Clin Proc201691111645166627814839
   PubMed Web of Science ®Google Scholar
• CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
   PubMed Web of Science ®Google Scholar
• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• PuiCHYangJJHungerSPChildhood Acute Lymphoblastic Leukemia Progress Through CollaborationJ Clin Oncol201533272938294826304874
   PubMed Web of Science ®Google Scholar
• PuiCHCampanaDPeiDTreating childhood acute lymphoblastic leukemia without cranial irradiationN Engl J Med2009360262730274119553647
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSSmithTLResults of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemiaJ Clin Oncol200018354756110653870
   PubMed Web of Science ®Google Scholar
• BoisselNAuclercMFLhéritierVShould adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trialsJ Clin Oncol200321577478012610173
   PubMed Web of Science ®Google Scholar
• RyttingMEJabbourEJJorgensenJLFinal results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenAm J Hematol201691881982327178680
   PubMed Web of Science ®Google Scholar
• HuguetFLeguayTRaffouxEPediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyJ Clin Oncol200927691191819124805
   PubMed Web of Science ®Google Scholar
• RoweJMBuckGBurnettAKInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood2005106123760376716105981
   PubMed Web of Science ®Google Scholar
• PullarkatVSlovakMLKopeckyKJFormanSJAppelbaumFRImpact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 studyBlood200811152563257218156492
   PubMed Web of Science ®Google Scholar
• GleissnerBGökbugetNBartramCRLeading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysisBlood20029951536154311861265
   PubMed Web of Science ®Google Scholar
• FieldingAKRoweJMBuckGUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaBlood2014123684385024277073
   PubMed Web of Science ®Google Scholar
• RavandiFO’BrienSThomasDFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaBlood2010116122070207720466853
   PubMed Web of Science ®Google Scholar
• MoormanAVNew and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemiaHaematologica2016101440741627033238
   PubMed Web of Science ®Google Scholar
• Jabber Al-ObaidiMSMartineauMBennettCFETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemiaLeukemia200216466967411960348
   PubMed Web of Science ®Google Scholar
• ChiltonLBuckGHarrisonCJHigh hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcomeLeukemia20142871511151824352198
   PubMed Web of Science ®Google Scholar
• MoormanAVEnsorHMRichardsSMPrognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trialLancet Oncol201011542943820409752
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 12016 Available from: https://www.nccn.org/professionals/physician_gls/default.aspxAccessed September 12, 2018
   Google Scholar
• PfeiferHRaumKMarkovicSGenomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation13Blood2018131131464147529348129
   PubMed Web of Science ®Google Scholar
• RobertsKGLiYPayne-TurnerDTargetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaN Engl J Med2014371111005101525207766
   PubMed Web of Science ®Google Scholar
• MullighanCGSuXZhangJDeletion of IKZF1 and prognosis in acute lymphoblastic leukemiaN Engl J Med2009360547048019129520
   PubMed Web of Science ®Google Scholar
• RobertsKGMorinRDZhangJGenetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemiaCancer Cell201222215316622897847
   PubMed Web of Science ®Google Scholar
• HarveyRCMullighanCGChenIMRearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaBlood2010115265312532120139093
   PubMed Web of Science ®Google Scholar
• YokotaTKanakuraYGenetic abnormalities associated with acute lymphoblastic leukemiaCancer Sci2016107672172526991355
   PubMed Web of Science ®Google Scholar
• HarrisonCJHaasOHarbottJDetection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study groupBr J Haematol2010151213214220701601
   PubMed Web of Science ®Google Scholar
• ReichardKKKangHRobinettSPediatric B-lymphoblastic leukemia with RUNX1 amplification: clinicopathologic study of eight casesMod Pathol201124121606161121822204
   PubMed Web of Science ®Google Scholar
• MoormanAVRichardsSMRobinsonHMPrognosis of children with acute lymphoblastic leukemia (ALL) and intra-chromosomal amplification of chromosome 21 (iAMP21Blood200710962327233017095619
   PubMed Web of Science ®Google Scholar
• LeonardJPMartinPRobozGJPractical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute LeukemiaJ Clin Oncol201735232708271528654364
   PubMed Web of Science ®Google Scholar
• DyerMJAkasakaTCapassoMImmunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?Blood201011581490149920042721
   PubMed Web of Science ®Google Scholar
• RussellLJEnshaeiAJonesLIGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcomeJ Clin Oncol201432141453146224711557
   PubMed Web of Science ®Google Scholar
• MullighanCGCollins-UnderwoodJRPhillipsLARearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemiaNat Genet200941111243124619838194
   PubMed Web of Science ®Google Scholar
• RussellLJCapassoMVaterIDeregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemiaBlood2009114132688269819641190
   PubMed Web of Science ®Google Scholar
• BassanRSpinelliOOldaniEImproved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood2009113184153416219141862
   PubMed Web of Science ®Google Scholar
• RiberaJMOriolAMorgadesMTreatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trialJ Clin Oncol201432151595160424752047
   PubMed Web of Science ®Google Scholar
• SchrappeMValsecchiMGBartramCRLate MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyBlood201111882077208421719599
   PubMed Web of Science ®Google Scholar
• ConterVBartramCRValsecchiMGMolecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyBlood2010115163206321420154213
   PubMed Web of Science ®Google Scholar
• GökbugetNKnebaMRaffTAdult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapiesBlood201212091868187622442346
   PubMed Web of Science ®Google Scholar
• BrüggemannMRaffTFlohrTClinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood200610731116112316195338
   PubMed Web of Science ®Google Scholar
• BeldjordKChevretSAsnafiVOncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaBlood2014123243739374924740809
   PubMed Web of Science ®Google Scholar
• SzczepańskiTBeishuizenAPongers-WillemseMJCross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual diseaseLeukemia199913219620510025893
   PubMed Web of Science ®Google Scholar
• van DongenJJLhermitteLBöttcherSEuroFlow antibody panels for standardized n-dimensional flow cytometric immunophe-notyping of normal, reactive and malignant leukocytesLeukemia20122691908197522552007
   PubMed Web of Science ®Google Scholar
• WuDSherwoodAFrommRHigh-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemiaSci Transl Med20124134ra63
   Web of Science ®Google Scholar
• WoodBWuDCrossleyBMeasurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALLBlood2018131121350135929284596
   PubMed Web of Science ®Google Scholar
• Coustan-SmithESanchoJHancockMLUse of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemiaBlood200210072399240212239148
   PubMed Web of Science ®Google Scholar
• van der VeldenVHJacobsDCWijkhuijsAJMinimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALLLeukemia20021681432143612145681
   PubMed Web of Science ®Google Scholar
• BriscoMJSykesPJHughesEMonitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemiaBr J Haematol19979923143199375747
   PubMed Web of Science ®Google Scholar
• van DongenJJvan der VeldenVHBrüggemannMOrfaoAMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlood2015125263996400925999452
   PubMed Web of Science ®Google Scholar
• Al UstwaniOGuptaNBakhribahHGriffithsEWangEWetzlerMClinical updates in adult acute lymphoblastic leukemiaCrit Rev Oncol Hematol20169918919926777876
   PubMed Web of Science ®Google Scholar
• RaffTGökbugetNLüschenSMolecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trialsBlood2007109391091517023577
   PubMed Web of Science ®Google Scholar
• StockWLaMSanfordBWhat determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studiesBlood200811251646165418502832
   PubMed Web of Science ®Google Scholar
• RyttingMEThomasDAO’BrienSMAugmented Berlin-Frank-furt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)Cancer2014120233660366825042398
   PubMed Web of Science ®Google Scholar
• StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
   PubMed Web of Science ®Google Scholar
• AdvaniASanfordBLugerSFrontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)Blood20131223903
   Web of Science ®Google Scholar
• LarsenECSalzerWLDevidasMComparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group Study AALL0232Journal of Clinical Oncology20112918 Suppl3
   Web of Science ®Google Scholar
• HuguetFChevretSLeguayTIntensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical TrialJ Clin Oncol2018 JCO.2017.76.819
   Google Scholar
• FieldingAKRoweJMRichardsSMProspective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Blood2009113194489449619244158
   PubMed Web of Science ®Google Scholar
• RavandiFO’BrienSMCortesJELong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaCancer2015121234158416426308885
   PubMed Web of Science ®Google Scholar
• RavandiFOthusMO’BrienSMUS Intergroup Study of Chemotherapy Plus Dasatinib Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALLBlood Adv20161325025929046900
   PubMed Web of Science ®Google Scholar
• KimDYJooYDLimSNNilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemiaBlood2015126674675626065651
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHRavandiFCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyLancet Oncol201516151547155526432046
   PubMed Web of Science ®Google Scholar
• HuYLiuYPelletierSRequirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemiaNat Genet200436545346115098032
   PubMed Web of Science ®Google Scholar
• PorkkaKKoskenvesaPLundánTDasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaBlood200811241005101218477770
   PubMed Web of Science ®Google Scholar
• RavandiFJorgensenJLThomasDADetection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyBlood201312271214122123836561
   PubMed Web of Science ®Google Scholar
• SoveriniSde BenedittisCPapayannidisCDrug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvementCancer201412071002100924382642
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHShahNPPonatinib in refractory Philadelphia chromosome-positive leukemiasN Engl J Med2012367222075208823190221
   PubMed Web of Science ®Google Scholar
• O’HareTShakespeareWCZhuXAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceCancer Cell200916540141219878872
   PubMed Web of Science ®Google Scholar
• SasakiKJabbourEJRavandiFHyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisCancer2016122233650365627479888
   PubMed Web of Science ®Google Scholar
• ChiarettiSVitaleAEliaLFirst results of the multicenter total therapy gimema LAL 1509 protocol for de novo adult philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) patientsBlood2014124797
   Web of Science ®Google Scholar
• MartinelliGPiciocchiAPapayannidisCFirst Report of the Gimema LAL 1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaASH201713099
   Google Scholar
• OttmannOGPfeiferHCayuelaJMNilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1 positive acute lympho- blastic leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL-PH-02)Blood2014124798
   Web of Science ®Google Scholar
• RousselotPCoudéMMGokbugetNDasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLBlood2016128677478227121472
   PubMed Web of Science ®Google Scholar
• ChalandonYThomasXHayetteSRandomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemiaBlood2015125243711371925878120
   PubMed Web of Science ®Google Scholar
• SchultzKRBowmanWPAledoAImproved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group studyJ Clin Oncol200927315175518119805687
   PubMed Web of Science ®Google Scholar
• SchultzKRCarrollAHeeremaNALong-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031Leukemia20142871467147124441288
   PubMed Web of Science ®Google Scholar
• WetzlerMWatsonDStockWAutologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)Haematologica201499111111524077846
   PubMed Web of Science ®Google Scholar
• GiebelSLabopinMGorinNCImproving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow TransplantationEur J Cancer201450241141724210524
   PubMed Web of Science ®Google Scholar
• PfeiferHWassmannBBethgeWRandomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemiaLeukemia20132761254126223212150
   PubMed Web of Science ®Google Scholar
• WassmannBPfeiferHStadlerMEarly molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Blood2005106245846315817679
   PubMed Web of Science ®Google Scholar
• KebriaeiPSalibaRRondonGLong-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomesBiol Blood Marrow Transplant201218458459221867666
   PubMed Web of Science ®Google Scholar
• GiebelSCzyzAOttmannOUse of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationCancer2016122192941295127309127
   PubMed Web of Science ®Google Scholar
• TavernierEBoironJMHuguetFOutcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia20072191907191417611565
   PubMed Web of Science ®Google Scholar
• ThomasDAKantarjianHSmithTLPrimary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapyCancer19998671216123010506707
   PubMed Web of Science ®Google Scholar
• PiccalugaPPArpinatiMCandoniASurface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemiaLeuk Lymphoma201152232532721077738
   PubMed Web of Science ®Google Scholar
• RaponiSde ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
   PubMed Web of Science ®Google Scholar
• ThomasDAFaderlSO’BrienSChemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaCancer200610671569158016502413
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSFaderlSChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJ Clin Oncol201028243880388920660823
   PubMed Web of Science ®Google Scholar
• NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
   PubMed Web of Science ®Google Scholar
• ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• GökbugetNZugmaierGKlingerMLong-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lympho-blastic leukemiaHaematologica20171024e132e13528082340
   PubMed Web of Science ®Google Scholar
• GökbugetNZugmaierGKlingerMLong-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemiaBlood201512623680
   Web of Science ®Google Scholar
• ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• KantarjianHSteinAGökbugetNBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaN Engl J Med2017376983684728249141
   PubMed Web of Science ®Google Scholar
• MartinelliGBoisselNChevallierPComplete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyJ Clin Oncol201735161795180228355115
   PubMed Web of Science ®Google Scholar
• von StackelbergALocatelliFZugmaierGPhase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaJ Clin Oncol201634364381438927998223
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteBlinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02143414. NLM identifier: NCT02143414Accessed August 16, 2018
   Google Scholar
• National Cancer InstituteCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02003222. NLM identifier: NCT02003222Accessed August 16, 2018
   Google Scholar
• GökbugetNDombretHBonifacioMBlinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaBlood2018131141522153129358182
   PubMed Web of Science ®Google Scholar
• HinmanLMHamannPRWallaceRMenendezATDurrFEUpeslacisJPreparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibioticsCancer Res19935314333633428324745
   PubMed Web of Science ®Google Scholar
• ThomasXInotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemiaExpert Opin Investig Drugs2012216871878
   PubMed Web of Science ®Google Scholar
• KantarjianHThomasDJorgensenJInotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyLancet Oncol201213440341122357140
   PubMed Web of Science ®Google Scholar
• KantarjianHThomasDJorgensenJResults of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaCancer2013119152728273623633004
   PubMed Web of Science ®Google Scholar
• KantarjianHRavandiFShortNJInotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyLancet Oncol201819224024829352703
   PubMed Web of Science ®Google Scholar
• KantarjianHMDeangeloDJStelljesMInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaN Engl J Med2016375874075327292104
   PubMed Web of Science ®Google Scholar
• JabbourEJDeangeloDJStelljesMEfficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATECancer201812481722173229381191
   PubMed Web of Science ®Google Scholar
• TurtleCJHanafiLABergerCCD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJ Clin Invest201612662123213827111235
   PubMed Web of Science ®Google Scholar
• LeeDWKochenderferJNStetler-StevensonMT cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialLancet2015385996751752825319501
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar
• DavilaMLRiviereIWangXEfficacy and toxicity management of 19-28z CART cell therapy in B cell acute lymphoblastic leukemiaSci Transl Med20146224224ra25
   PubMed Web of Science ®Google Scholar
• GruppSALaetschTWBuechnerJAnalysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Blood2016128221
   Web of Science ®Google Scholar
• MaudeSLPulsipherMABoyerMWEfficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim AnalysisBlood20161282801
   Web of Science ®Google Scholar
• ParkJHRivièreIGonenMLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaN Engl J Med2018378544945929385376
   PubMed Web of Science ®Google Scholar
• WeiGWangJHuangHZhaoYNovel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemiaJ Hematol Oncol201710115028821272
   PubMed Web of Science ®Google Scholar
• RietTHolzingerADörrieJSchaftNSchulerGAbkenHNon-viral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapyMethods Mol Biol201396918720123296935
   PubMedGoogle Scholar
• HasoWLeeDWShahNNAnti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBlood201312171165117423243285
   PubMed Web of Science ®Google Scholar
• CaiBGuoMWangYCo-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemiaJ Hematol Oncol20169113127887660
   PubMed Web of Science ®Google Scholar
• MrózekKHeeremaNABloomfieldCDCytogenetics in acute leukemiaBlood Rev200418211513615010150
   PubMed Web of Science ®Google Scholar